These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 35751974)
1. Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein. Lim H; Kim SE; Lee YH; Hwang YH; Kim SH; Kim MY; Chung GT; Kim YJ; Kim D; Lee JA Virology; 2022 Aug; 573():118-123. PubMed ID: 35751974 [TBL] [Abstract][Full Text] [Related]
2. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z; Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794 [TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
5. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2021; 12():824728. PubMed ID: 35154086 [TBL] [Abstract][Full Text] [Related]
6. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595 [TBL] [Abstract][Full Text] [Related]
7. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
8. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
9. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins. Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
12. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
13. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein. Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955 [TBL] [Abstract][Full Text] [Related]
14. A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. Martins M; do Nascimento GM; Conforti A; Noll JCG; Impellizeri JA; Sanchez E; Wagner B; Lione L; Salvatori E; Pinto E; Compagnone M; Viscount B; Hayward J; Shorrock C; Aurisicchio L; Diel DG Arch Virol; 2023 Mar; 168(4):124. PubMed ID: 36988739 [TBL] [Abstract][Full Text] [Related]
15. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract. Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008 [TBL] [Abstract][Full Text] [Related]
16. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants. Kim SE; Park SH; Park WJ; Kim G; Kim SY; Won H; Hwang YH; Lim H; Kim HG; Kim YJ; Kim D; Lee JA PLoS One; 2023; 18(12):e0295594. PubMed ID: 38060612 [TBL] [Abstract][Full Text] [Related]
18. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection. Clever S; Limpinsel L; Meyer Zu Natrup C; Schünemann LM; Beythien G; Rosiak M; Hülskötter K; Gregor KM; Tuchel T; Kalodimou G; Freudenstein A; Kumar S; Baumgärtner W; Sutter G; Tscherne A; Volz A Viruses; 2024 Mar; 16(3):. PubMed ID: 38543782 [TBL] [Abstract][Full Text] [Related]
19. DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss. Chai KM; Tzeng TT; Shen KY; Liao HC; Lin JJ; Chen MY; Yu GY; Dou HY; Liao CL; Chen HW; Liu SJ PLoS Negl Trop Dis; 2021 May; 15(5):e0009374. PubMed ID: 34043618 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]